Vasilis Spyridon Tseriotis

Dr. Vasilis Spyridon Tseriotis

Laboratory of Clinical Pharmacology, Aristotle University of Thessaloniki, Thessaloníki, Kentrikí Makedonía, Greece
+1
orcid

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Vasilis Spyridon TseriotisVasilis Spyridon Tseriotis
Vasilis Spyridon Tseriotis
DADimitrios Ampazis
Dimitrios Ampazis
Sofia KarachrysafiSofia Karachrysafi
Sofia Karachrysafi
Theodora PapamitsouTheodora Papamitsou
Theodora Papamitsou
GPGeorgios Petrakis
Georgios Petrakis
MAMarianthi Arnaoutoglou
Marianthi Arnaoutoglou
Cancer, a leading global cause of death responsible for nearly 10 million deaths annually, demands innovative therapeutic strategies. Intrinsic cytotoxicity and biocompatibility of zinc oxide nanoparticles (ZnO-NPs) have rendered them promising nanoplatforms in oncology. We herein systematically review their applications for targeted cancer chemotherapy, with a focus on physicochemical properties, drug delivery mechanisms, and interactions with the tumor microenvironment (TME). We searched PubMed, SCOPUS, and Web of Science from inception through December 2024 for peer-reviewed preclinical studies on cancer models. Results were qualitatively synthesized. Quality was assessed with the SYRCLE risk of bias tool. Among 20 eligible studies, ZnO-NPs were frequently functionalized with ligands to enhance tumor targeting and minimize systemic toxicity. Chemotherapeutic agents (doxorubicin, 5-fluorouracil, docetaxel, cisplatin, gemcitabine, and tirapazamine) were loaded into ZnO-based carriers, with improved anticancer efficacy compared to free drug formulations, particularly in multidrug-resistant cell lines and in vivo murine xenografts. The mildly acidic TME was exploited for pH-responsive drug release, premature leakage reduction, and improvement of intratumoral accumulation. Enhanced therapeutic outcomes were attributed to reactive oxygen species generation, zinc ion-mediated cytotoxicity, mitochondrial dysfunction, and efflux pump inhibition. Deep tumor penetration, apoptosis induction, and tumor growth suppression were also reported, with minimal toxicity to healthy tissues. ZnO-NPs might constitute a versatile and promising strategy for targeted cancer chemotherapy, offering synergistic anticancer effects and improved safety profiles. Future studies emphasizing long-term toxicity, immune responses, and scalable production could lead to clinical translation of ZnO-based nanomedicine in oncology.

17 December 2024 in Movement Disorders Clinical Practice
Verified
Journal Article
Open access
Vasilis Spyridon TseriotisVasilis Spyridon Tseriotis
Vasilis Spyridon Tseriotis
KEKyriaki Eleftheriadou
Kyriaki Eleftheriadou
TMTheodoros Mavridis
Theodoros Mavridis
GKGeorgios Konstantis
Georgios Konstantis
BFBjoern Falkenburger
Bjoern Falkenburger
MAMarianthi Arnaoutoglou
Marianthi Arnaoutoglou
Background: Loss of dorsolateral nigral hyperintensity (DNH) in iron‐sensitive sequences of Magnetic Resonance Imaging (MRI), also described as “swallow tail sign” (STS) loss, has shown promising diagnostic value in Parkinson's Disease (PD) and Atypical Parkinsonian Syndromes (APS).Objective: To conduct a bibliometric analysis on substantia nigra MRI and a systematic review on the clinical utility of STS visual assessment on Susceptibility‐Weighted Imaging in various clinical entities.Methods: VOSviewer's keyword co‐occurrence network was employed using Web of Science (WOS). Complying with the PRISMA statement, we searched MEDLINE, WOS, SCOPUS, ProQuest and Google Scholar for peer‐reviewed studies conducted in vivo, excluding quantitative imaging techniques.Results: DNH is a relatively novel parameter in substantia nigra MRI literature. Our SWI‐focused review included 42 studies (3281 patients). Diagnostic accuracy of STS loss for PD/APS differentiation from controls and for Lewy Body Dementia differentiation from other dementias was 47.8–98.5% and 76–90%, respectively, with poorer capacity, however, in delineating PD from APS. STS evaluation in idiopathic REM sleep behavior disorder, a sign of prodromal PD, was typically concordant with nuclear scans, identifying subjects with high conversion risk. Iron deposition can affect STS in Multiple Sclerosis and STS loss in Amyotrophic Lateral Sclerosis is linked with multisystem degeneration, with poorer prognosis. In healthy individuals iron‐induced microvessel changes are suspected for false positive results.Conclusion: STS assessment exhibits potential in different settings, with a possibly intermediate role in the diagnostic work‐up of various conditions. Its clinical utility should be explored further, through standardized MRI protocols on larger cohorts.

27 May 2024 in Journal of Neurology
Verified
Journal Article
Closed access
PDF file
Vasilis Spyridon TseriotisVasilis Spyridon Tseriotis
Vasilis Spyridon Tseriotis
Theodoros MavridisTheodoros Mavridis
Theodoros Mavridis
KEKyriaki Eleftheriadou
Kyriaki Eleftheriadou
GKGeorgios Konstantis
Georgios Konstantis
David-Dimitris ChlorogiannisDavid-Dimitris Chlorogiannis
David-Dimitris Chlorogiannis
SKSpiros Konitsiotis
Spiros Konitsiotis

5 September 2025 in Neurology International
Verified
Journal Article
Open access
PDF file
Aleksandar Z. SičAleksandar Z. Sič
Aleksandar Z. Sič
CGConor Philip George
Conor Philip George
DGDaniela Ferrer Gonzalez
Daniela Ferrer Gonzalez
Vasilis Spyridon TseriotisVasilis Spyridon Tseriotis
Vasilis Spyridon Tseriotis
Nebojsa Nick KnezevicNebojsa Nick Knezevic
Nebojsa Nick Knezevic
Cannabinoids have gained increasing attention as potential therapeutic agents in chronic pain management. Their mechanisms of action, mediated through CB1 and CB2 receptors, provide a pharmacological alternative to conventional analgesics. The evidence is strongest for neuropathic pain and multiple sclerosis-related spasticity, while the results for fibromyalgia, osteoarthritis, and musculoskeletal pain remain inconsistent. The average pain reduction is modest, often not exceeding 0.5–1.0 points on a 10-point scale, and therapeutic gains are offset by safety concerns. Quantitative data show that discontinuation rates range from 4.3% at low-dose CBD to 12.9% at high-dose CBD, compared with 3.5% on placebo, while nabiximols (THC + CBD spray) are associated with dizziness in 25% of patients, somnolence in 8%, and treatment discontinuation in 12%. High-dose CBD also carries a measurable risk of hepatotoxicity. Regulatory heterogeneity further constrains trial feasibility, scalability, and patient access, with disparities evident across the United States, Europe, Canada, and Australia. Overall, cannabinoids provide modest, condition-specific analgesia and should be considered adjunctive rather than first-line options, reserved for patients unresponsive to conventional therapy. Future progress requires standardized formulations, harmonized international regulations, long-term safety data, and large-scale randomized controlled trials to clarify their role in evidence-based pain management.

26 November 2025 in NeuroSci
Verified
Journal Article
Open access
PDF file
Aleksandar Z. SičAleksandar Z. Sič
Aleksandar Z. Sič
Vasilis Spyridon TseriotisVasilis Spyridon Tseriotis
Vasilis Spyridon Tseriotis
BBBozidar Belanovic
Bozidar Belanovic
MNMarko Nemet
Marko Nemet
Marko BaralićMarko Baralić
Marko Baralić
Stroke is the second-largest cause of death and disability worldwide, and many patients require intensive care for airway compromise, hemodynamic instability, cerebral edema, or systemic complications. This review summarizes key aspects of ICU management in both acute ischemic stroke (AIS) and hemorrhagic stroke (HS). Priorities are airway protection, oxygenation, individualized blood pressure targets, and strict control of temperature and glucose. Neurological monitoring and prompt management of intracranial pressure (ICP), together with timely surgical interventions (hemicraniectomy or hematoma evacuation), are central to acute care. Seizures are treated promptly, while routine prophylaxis is not recommended. Prevention of aspiration pneumonia, venous thromboembolism, infections, and other intensive care unit (ICU) complications is essential, along with early nutrition, mobilization, and rehabilitation. Prognosis and decisions about intensity of care require shared discussions with families and involvement of palliative services, when appropriate. Many practices remain based on observational data or extrapolation from other populations, underlining the need for stroke-specific clinical trials. Outcomes are consistently better when patients are managed in specialized stroke or neurocritical care units with a multidisciplinary treatment approach

14 December 2024 in Neurological Sciences
Verified
Journal Article
Closed access
PDF file
LALiampas Andreas
Liampas Andreas
Vasilis Spyridon TseriotisVasilis Spyridon Tseriotis
Vasilis Spyridon Tseriotis
Theodoros MavridisTheodoros Mavridis
Theodoros Mavridis
GVGeorge D. Vavougios
George D. Vavougios
Panagiotis ZisPanagiotis Zis
Panagiotis Zis
Artemios ArtemiadisArtemios Artemiadis
Artemios Artemiadis